PharmaCyte Biotech Q1 2024 Earnings Report $1.64 0.00 (0.00%) (As of 12/20/2024 05:16 PM ET) Earnings History PharmaCyte Biotech EPS ResultsActual EPS-$0.28Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/APharmaCyte Biotech Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/APharmaCyte Biotech Announcement DetailsQuarterQ1 2024Date9/18/2023TimeN/AConference Call ResourcesPMCB Earnings History The #1 Coin for November 2024 (Ad)Grayscale Investments just announced a new fund offering access to a HOT new DeFi coin… And thanks to this newly established trust, I believe this coin could skyrocket up to 150x+ in the next 30 days alone! I've compiled everything you need to know about this once-in-a-lifetime DeFi project into a brand-new comprehensive guide… You can get access to the report by clicking here now… PharmaCyte Biotech Earnings HeadlinesHead-To-Head Analysis: PharmaCyte Biotech (NASDAQ:PMCB) & Coeptis Therapeutics (NASDAQ:COEP)December 16, 2024 | americanbankingnews.comMyMD Pharmaceuticals Secures Strategic InvestmentsMay 21, 2024 | businesswire.comThe #1 Coin for November 2024Grayscale Investments just announced a new fund offering access to a HOT new DeFi coin… And thanks to this newly established trust, I believe this coin could skyrocket up to 150x+ in the next 30 days alone! I've compiled everything you need to know about this once-in-a-lifetime DeFi project into a brand-new comprehensive guide… December 22, 2024 | Crypto 101 Media (Ad)PharmaCyte Biotech Makes $7 Million Strategic Investment in MyMD, A Biopharmaceutical Company Focused on Inflammatory DiseaseMay 21, 2024 | businesswire.comPMCB Stock Earnings: PharmaCyte Biotech Reported Results for Q2 2024December 18, 2023 | msn.comCompanies Like PharmaCyte Biotech (NASDAQ:PMCB) Are In A Position To Invest In GrowthDecember 15, 2023 | finance.yahoo.comSee More PharmaCyte Biotech Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like PharmaCyte Biotech? Sign up for Earnings360's daily newsletter to receive timely earnings updates on PharmaCyte Biotech and other key companies, straight to your email. Email Address About PharmaCyte BiotechPharmaCyte Biotech (NASDAQ:PMCB), a biotechnology company, develops and commercializes cellular therapies for cancer in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer. The company develops CypCaps for pancreatic cancer and other solid cancerous tumors. It has a cooperation agreement with Iroquois Master Fund Ltd.; and license agreements with SG Austria Pte. Ltd. and Austrianova Singapore Pte. Ltd. to use the Cell-in-the-Box technology for cancer treatment. The company was formerly known as Nuvilex, Inc. and changed its name to PharmaCyte Biotech, Inc. in January 2015. PharmaCyte Biotech, Inc. was incorporated in 1996 and is headquartered in Las Vegas, Nevada.View PharmaCyte Biotech ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles History Hints at a Rebound for Toll Brothers After EarningsAlibaba Stock: Why Earnings Make It a Buy Despite the Recent DipMercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead?Apple Earnings - When Really Good Just Isn’t Good Enough Roblox Stock Set for More Gains After Strong Earnings ReportAmazon: Why Analysts Think It's a Solid Buy Ahead of Earnings Upcoming Earnings Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
